Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.
Level 4 - case-series / case-control
Case series describing rechallenge in 3 patients
What was done
Three patients who developed drug-induced hepatitis during treatment with sustained-release niacin were rechallenged with equivalent or higher doses of crystalline niacin to assess recurrence of hepatocellular damage.
What was found
All three patients tolerated crystalline niacin at equivalent or higher doses with no evidence of recurring hepatocellular damage. The abstract reports no numerical values, laboratory measurements, or specific dosages.
Why it matters
These cases support observations that sustained-release niacin may be more hepatotoxic than crystalline formulations and indicate that some patients experiencing toxicity from sustained-release preparations can tolerate crystalline niacin.
Limits
The sample size is extremely small (n = 3) with no control group. The abstract does not provide exact dosages, duration of exposure or rechallenge, baseline patient characteristics, or specific liver enzyme values. The biological mechanism remains unknown.
Cited by
- supports In published literature, liver toxicity from niacin is associated with time-released formulations rather than immediate-release free niacin.